Defining G protein–coupled receptor ligand efficacy and biased agonism in precise chemical terms is one challenge posed by the current structural data that exists for this receptor family. Concepts classically used for understanding enzymes and other nonreceptor proteins may lead us in the right direction.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Reconstruction of apo A2A receptor activation pathways reveal ligand-competent intermediates and state-dependent cholesterol hotspots
Scientific Reports Open Access 02 October 2019
-
Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach
Scientific Reports Open Access 14 March 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Palczewski, K. et al. Science 289, 739–745 (2000).
Salon, J.A., Lodowski, D.T. & Palczewski, K. Pharmacol. Rev. 63, 901–937 (2011).
Fanelli, F. & De Benedetti, P.G. Chem. Rev. 111, PR438–PR535 (2011).
Rasmussen, S.G.F. et al. Nature 477, 549–555 (2011).
Rosenbaum, D.M. et al. Nature 469, 236–240 (2011).
Warne, T. et al. Nature 469, 241–244 (2011).
Xu, F. et al. Science 332, 322–327 (2011).
Kenakin, T.P. A Pharmacology Primer: Theory, Applications, and Methods 3rd Ed. (Elsevier, 2009).
Rasmussen, S.G.F. et al. Nature 469, 175–180 (2011).
Monod, J., Wyman, J. & Changeux, J.P. J. Mol. Biol. 12, 88–118 (1965).
Koshland, D.E. Jr., Némethy, G. & Filmer, D. Biochemistry 5, 365–385 (1966).
Tsai, C.J., Del Sol, A. & Nussinov, R. Mol. Biosyst. 5, 207–216 (2009).
Cui, Q. & Karplus, M. Protein Sci. 17, 1295–1307 (2008).
Frauenfelder, H., Parak, F. & Young, R.D. Annu. Rev. Biophys. Biophys. Chem. 17, 451–479 (1988).
Freire, E. Proc. Natl. Acad. Sci. USA 97, 11680–11682 (2000).
Cooper, A. & Dryden, D.T. Eur. Biophys. J. 11, 103–109 (1984).
Onaran, H.O. & Costa, T. Curr. Protein Pept. Sci. 10, 110–115 (2009).
Wyman, J. J. Mol. Biol. 11, 631–644 (1965).
Weber, G. Biochemistry 11, 864–878 (1972).
De Lean, A., Stadel, J.M. & Lefkowitz, R.J. J. Biol. Chem. 255, 7108–7117 (1980).
Samama, P., Cotecchia, S., Costa, T. & Lefkowitz, R.J. J. Biol. Chem. 268, 4625–4636 (1993).
Kenakin, T. Mol. Pharmacol. 72, 1393–1401 (2007).
Rajagopal, S., Rajagopal, K. & Lefkowitz, R.J. Nat. Rev. Drug Discov. 9, 373–386 (2010).
Krupnick, J.G. & Benovic, J.L. Annu. Rev. Pharmacol. Toxicol. 38, 289–319 (1998).
Rajagopal, S. et al. Mol. Pharmacol. 80, 367–377 (2011).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Onaran, H., Costa, T. Where have all the active receptor states gone?. Nat Chem Biol 8, 674–677 (2012). https://doi.org/10.1038/nchembio.1024
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1024
This article is cited by
-
Reconstruction of apo A2A receptor activation pathways reveal ligand-competent intermediates and state-dependent cholesterol hotspots
Scientific Reports (2019)
-
Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach
Scientific Reports (2017)
-
Signalling bias in new drug discovery: detection, quantification and therapeutic impact
Nature Reviews Drug Discovery (2013)